Myriad Genetics (MYGN) CSO gets 173,196 RSUs, withholds 37,799 shares

Rhea-AI Filing Summary

Myriad Genetics Chief Scientific Officer Dale Muzzey reported equity compensation activity and related tax withholding transactions in company stock. On March 12, 2026, he received 173,196 time-based restricted stock units under the 2017 equity incentive plan, each representing one share of common stock vesting in three equal annual installments beginning on the first anniversary of the grant.

On March 13–15, 2026, a total of 37,799 shares of common stock were withheld by the company at $4.66 per share to satisfy tax obligations on the vesting of previously granted time-based and performance-based restricted stock units. These F-code transactions are share-withholding for taxes rather than open-market sales. After these transactions, Muzzey directly holds 329,275 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muzzey Dale

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		A		173,196(1)	A	$0	367,074	D
Common Stock	03/13/2026		F		12,779(2)	D	$4.66	354,295	D
Common Stock	03/14/2026		F		8,288(2)	D	$4.66	346,007	D
Common Stock	03/15/2026		F		4,783(2)	D	$4.66	341,224	D
Common Stock	03/15/2026		F		11,949(3)	D	$4.66	329,275	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

2. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.

3. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of the Issuer's Common Stock on March 13, 2026.

Remarks:

	By: Justin Hunter For: Dale Muzzey	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MYRIAD GENETICS (MYGN) report for Dale Muzzey?

MYRIAD GENETICS reported that Chief Scientific Officer Dale Muzzey received 173,196 restricted stock units and had 37,799 shares withheld to cover tax obligations related to vesting awards, leaving him with 329,275 shares of common stock held directly after these transactions.

Was the MYGN insider activity a stock sale by the Chief Scientific Officer?

The reported MYGN insider activity was not an open-market sale. Shares were withheld by the company to satisfy tax obligations on vesting restricted stock units, a common non-market transaction that reduces the number of newly delivered shares without involving public market selling.

How many MYGN restricted stock units were granted to the Chief Scientific Officer?

Dale Muzzey received 173,196 time-based restricted stock units of MYGN common stock. Each unit represents a contingent right to one share and vests in three equal annual installments starting on the first anniversary of the grant date under the 2017 equity incentive plan.

How many MYGN shares were withheld for taxes in these insider transactions?

A total of 37,799 MYGN shares were withheld by the company to satisfy tax withholding obligations. These shares related to the vesting of previously granted time-based and performance-based restricted stock units, with withholding amounts based on the March 13, 2026 closing stock price.

What is Dale Muzzey’s MYGN shareholding after the reported Form 4 transactions?

Following the Form 4 transactions, Chief Scientific Officer Dale Muzzey directly holds 329,275 shares of MYGN common stock. This balance reflects the new restricted stock unit grant and the shares withheld by the company to satisfy tax obligations on vesting awards.

How do the MYGN restricted stock units for the Chief Scientific Officer vest over time?

The 173,196 MYGN restricted stock units granted to the Chief Scientific Officer vest in three equal annual installments. Vesting begins on the first anniversary of the grant date, aligning delivery of shares with continued service under the 2017 Employee, Director and Consultant Equity Incentive Plan.